Circulation, Vol 78, 1394-1400, Copyright © 1988 by American Heart Association
E Grossman, S Oren, GE Garavaglia, FH Messerli and ED Frohlich
The hemodynamic effects of 3 months of nitrendipine therapy were evaluated
in 14 patients with mild to moderate essential hypertension. Nitrendipine
reduced systolic and diastolic pressures from 145 +/- 4/95 +/- 3 to 119 +/-
3/78 +/- 2 mm Hg, respectively, (p less than 0.001) through a fall in total
peripheral resistance index (46 +/- 4 to 34 +/- 3 units/m2, p less than
0.001) without associated reflex cardiac stimulation. This antihypertensive
effect was related directly to the height of pretreatment arterial pressure
(r = -0.67, p = 0.006) but not to age or pretreatment plasma renin
activity. Renal and forearm blood flow increased, vascular resistance
decreased, and glomerular filtration rate remained stable. In addition,
nitrendipine reduced left ventricular mass index (133 +/- 7 to 116 +/- 5
g/m2, p = 0.003) and wall thickness, changes that were accompanied by
improvement in diastolic as well as systolic (ejection fraction and
fractional fiber shortening rate) left ventricular functions. Intravascular
volume did not expand with reduction in pressure. This study provides new
information concerning the long-term hemodynamic effects and associated
echocardiographic changes with nitrendipine. It also provides the first
regional hemodynamic data in essential hypertensive patients detailing
forearm and splanchnic changes and renal blood flow increase during
prolonged treatment.
ARTICLES
Systemic and regional hemodynamic and humoral effects of nitrendipine in essential hypertension
Department of Internal Medicine, Ochsner Clinic, New Orleans, Louisiana.
This article has been cited by other articles:
![]() |
A. N. Botchway, M. A. Turner, D. J. Sheridan, N. A. Flores, and C. H. Fry Electrophysiological effects accompanying regression of left ventricular hypertrophy Cardiovasc Res, December 1, 2003; 60(3): 510 - 517. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kingsbury, A. Mahnke, M. Turner, and D. Sheridan Recovery of coronary function and morphology during regression of left ventricular hypertrophy Cardiovasc Res, July 1, 2002; 55(1): 83 - 96. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Frohlich Risk Mechanisms in Hypertensive Heart Disease Hypertension, October 1, 1999; 34(4): 782 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. D. Frohlich, D. Aristizabal, F. Soria, and F. H. Messerli Investigative Concerns in Demonstrating Reduced Risk from Reversing Left Ventricular Hypertrophy Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1996; 1(1): 17 - 22. [Abstract] [PDF] |
||||
![]() |
E. Grossman, J. Shemesh, A. Shamiss, M. Thaler, J. Carroll, and T. Rosenthal Left Ventricular Mass in Diabetes-Hypertension Arch Intern Med, May 1, 1992; 152(5): 1001 - 1004. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1988 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |